Pharmaceutical companies in the first half of the year: losses of more than 10 billion transformation al-innovative drugs.

Pharmaceutical Network July 31 - Under the epidemic, all walks of life have been affected to varying degrees, and the pharmaceutical industry is no exception.
reporter rough statistics, so far, more than 100 pharmaceutical companies have disclosed the first half of 2020 results report, the total loss of 13.04 billion yuan, has exceeded the 2019 full-year loss amount of 80%.
in addition to the impact of the volume of procurement, during the outbreak of hospital departments closed, etc. has become an important reason for the performance of a number of pharmaceutical enterprises.
industry insiders said that in the second half of the year, with the outbreak gradually under control, pharmaceutical enterprises will gradually be restored, performance has a certain recovery. in addition,
, under the trend of volume procurement, accelerating the transition to innovative drugs will be an important part of the second half of the domestic pharmaceutical enterprises.
21 companies are expected to lose more than 10 billion yuan in the first loss, and 21 companies are expected to lose the first loss... In the first half of 2020, pharmaceutical companies did not make as much money as the outside world thought. According
to data from the China Business Industry Research Institute, the total loss in the pharmaceutical industry in the first half of the year reached 13.04 billion yuan, compared with a total loss of 16.27 billion yuan for the whole of 2019.
reporters combed the financial results found that, unlike in previous years, the first half of this year to Meirui Medical, Huada Gene as the representative of the performance of medical device enterprises are relatively strong, while pharmaceutical companies showed a different decline in performance.
demand for devices such as ventilators has increased significantly, with Murray Medical, which specializes in in vitro diagnostics, medical imaging and other businesses, expected net profit of 3.27 billion to 3.51 billion yuan in the first half of 2020, an increase of 38%-48% YoY. similarly,
, the demand for new coronavirus testing kits increased, Huada Gene expects to achieve net profit of 1.53 billion to 1.63 billion yuan in the first half of the year, up more than 600% YoY, while medical protective equipment manufacturer Ingke Medical expects to achieve a net profit of 1.9 billion to 2.1 billion yuan in the first half, up more than 2500% YoY.
pharmaceutical companies, the first half of 2020 showed a different decline in performance.
mainly produces and sells products such as anti-infective respiratory drugs, the source medicine is expected to lose 72 million to 77 million yuan in the first half of the year, a decline of 280%. similarly,
, Asia-Pacific Pharmaceuticals, which mainly produces and sells chemical agents and chemical raw materials, is expected to post a first-half loss of 50 million to 60 million yuan, compared with a profit of 40 million yuan in the same period last year.
, Seto Bio, which is the main business in the production and sale of steroid pharmaceutical raw materials, expects a first-half loss of more than 30 million yuan, compared with a profit of more than 60 million yuan in the same period last year.
in addition, it is worth noting that there are 21 pharmaceutical companies such as Longjin Pharmaceuticals, Tiansheng Pharmaceuticals, Tonghua Jinma, Jiaying Pharmaceuticals and Asia Pacific Pharmaceuticals, which reported half-yearly losses for the first time.
Longjin Pharmaceutical smain business for the development, production and marketing of Chinese and Western medicine, the main products for Longjin injection lamp flower, is a high purity chinese medicine freeze-dried powder injection, mainly used for the treatment of cardiovascular diseases.
, according to the latest financial information, Longjin Pharmaceuticals expects to lose 1.324 million to 1.9536 million yuan in the first half of the year, net profit decreased by about 200% year-on-year.
since the listing, the net profit of Longjin Pharmaceuticals in the first half of 2015 to the first half of 2019 was RMB29.073 million, RMB33.881 million, RMB23.402 million, RMB109.225 million and RMB1.3401 million, respectively.
hospital demand reduction in addition to the volume of procurement, medical insurance payment and other policy impact, the new crown outbreak appears in the performance of the pharmaceutical companies in the reasons for changes.
" sales of the company's products and operating income declined from a year earlier due to the new crown outbreak and the continued implementation of health insurance payments and hospital prescription restrictions.
" Longjin Pharmaceuticals explains why the company's performance fell for the first time. similarly,
, the net profit of 30% decline in Jichuan Pharmaceuticals also said that by the new coronavirus pneumonia outbreak isolation measures, some hospitals routine outpatients failed to receive normal, medical institutions, such as pediatrics, the decline in the number of large, while the sale of drugstores also suffered a negative impact, resulting in a decline in the company's operating performance.
Jichuan Pharmaceuticals' main products are pedi-blue anti-inflammatory oral solution, pediatric anti-red hot particles, rebella sodium intestinal capsules and so on.
it is understood that the above drugs are prescription drugs, need to be purchased by prescription.
in recent years, in order to "break the drug-based medicine" mechanism, let the hospital return to the nature of medical treatment, weaken the "exclusive" of prescription, the state has introduced relevant policies to promote the outflow of prescriptions, so that the original completion of medical treatment in hospitals, prescription, access to medicines can no longer restrict the free flow of prescriptions, drugs provided by social pharmacies, medical treatment and drug separation.
, however, for the time being, the vast majority of prescription drug sales channels are still hospitals, during the outbreak, some departments are limited or even closed, directly affecting the production and sales of enterprises. Zhao Heng, founder of Latitude Health, a
healthcare strategy consultancy, said the new crown outbreak has had a impact on the short-term performance of the pharmaceutical industry and listed companies.
" during the outbreak, the demand for hospital-side medical services decreased, resulting in the use of related drugs and other simultaneousimpact, some enterprises declined performance.
" a hospital radiology department to provide medical radiation safety solutions for the head of the enterprise told reporters that during the outbreak, the hospital focused on prevention and control of the epidemic, other departments suspended office, the company and pharmaceutical production enterprises have no small impact.
"In our case, about 80% of the company's business comes from hospitals, the outbreak is under control, and the hospital is back to normal operations before our business can gradually recover," he said.
", "accelerated innovation transformation of the sudden outbreak more or less affect the sales performance of pharmaceutical companies, but also let pharmaceutical companies have more clearer thinking.
with the epidemic under control, the second half of the enterprise performance will pick up, but under the trend of the large rout of medical insurance control fees, accelerating the transition to innovation is an effective way to increase the ability to resist risks.
pharmaceutical industry investment analyst Li Wei told reporters that the second half of the year, with the outbreak gradually under control, pharmaceutical companies will gradually recover their business, performance has a certain recovery.
" Although the outbreak has had an impact on the short-term performance of the pharmaceutical sector, the performance of pharmaceutical listed companies has been more stable and less volatile than in other industries.
the industry's performance is expected to grow in the second half of the year against the backdrop of rapid resumption of production and recovery in medical demand.
" the main production of hospital ophthalmology outpatient surgery prescription drug xingqi eye medicine company director, deputy general manager, board secretary Zhang Shaoxuan said in the performance statement, with the epidemic under control, hospitals throughout the country have resumed work, the company's operating income is expected to gradually recover.
Also said that with the domestic epidemic gradually effectively controlled, in the second quarter of 2020, the company's overall operation gradually returned to normal, operating results compared to the first quarter has a certain degree of improvement.
in response to business recovery and other issues, Jiaying Pharmaceutical director-general did not make more responses, only to say that everything is subject to the announcement.
in Zhao Heng's view, the impact of the outbreak is only temporary, as the outbreak is controlled, business will also be restored, the outbreak, pharmaceutical companies need to consider how to increase the risk resistance in the context of the volume of procurement, medical insurance control fees and so on.
" from the sub-sector, during the outbreak, medical devices, innovative drugs, biological drugs maintained a certain growth rate, while Chinese medicine, chemical generics and other sectors downturn.
in the context of the country's continuous introduction of policies to encourage drug innovation, innovation leading enterprises will have good risk resistance.
", in fact, companies are aware of the importance of transformation and accelerating the transition to innovative medicine.
Yiyi Pharmaceuticals said in its 2020 half-year report that the company is actively expanding into innovative drugs and bio-innovative drugs.
the future, the company will be based on policy changes and market conditions, the use of a variety of ways to carry out new drug research and development work, continue to improve the company's drug research and development ladder, to achieve the company's sustainable development.
.